CNS Specific Antisense Oligonucleotide Market Size, Share, Growth, Outlook, and Opportunity Analysis, 2018-2026 Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modifcation of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development. Market Dynamics Increasing prevalence of neurodegenerative disease is a major factor driving CNS specifc antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.
Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2477
Increasing prevalence of cancer is expected to propel growth of the CNS specifc antisense oligonucleotide market CNS specifc antisense oligonucleotide is used for treatment of neurodegenerative disorders and associated rare diseases. According to February 2017, report of National Center for Biotechnology Information (NCBI), an estimated the prevalence of Cerebral palsy ranges from 1.5 to more than 4 per 1,000 of children from age 10 to 14 years. The birth prevalence of Cerebral palsy is around 2 per 1,000 live births globally. Furthermore, launch of new products for rare disease associated with CNS disorders is propelling growth of the CNS specifc antisense oligonucleotide market over the forecast period. For